ProCE Banner Activity

Managed Care Perspectives in the Implementation of BCMA-Directed Therapy in MM

Clinical Thought

Pharmacy experts highlight key points and managed care perspectives with the implementation of BCMA-directed therapy in relapsed/refractory multiple myeloma.

Released: May 10, 2024

Expiration: May 09, 2025

Share

Faculty

Rebecca Gonzalez

Rebecca Gonzalez, PharmD, BCOP

Blood and Marrow Transplant and Cellular Immunotherapy Clinical Pharmacist
Moffitt Cancer Center
Tampa, Florida

Melissa Pozotrigo

Melissa Pozotrigo, PharmD, BCOP

Senior Clinical Oncology Pharmacist
OncoHealth
Atlanta, Georgia

Provided by

Provided by ProCE, LLC in partnership with Clinical Care Options, LLC 

ProCE Banner

Supporters

Supported by an educational grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Partners

Clinical Care Options, LLC

ProCE Banner

Disclosure

Primary Author

Rebecca Gonzalez, PharmD, BCOP

Blood and Marrow Transplant and Cellular Immunotherapy Clinical Pharmacist
Moffitt Cancer Center
Tampa, Florida

Rebecca Gonzalez, PharmD, BCOP, has no relevant financial relationships to disclose.

Melissa Pozotrigo, PharmD, BCOP

Senior Clinical Oncology Pharmacist
OncoHealth
Atlanta, Georgia

Melissa Pozotrigo, PharmD, BCOP, has no relevant financial relationships to disclose.